These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31872359)

  • 1. The link between interleukin-1β and acute myocardial infarction in chronic myeloid leukemia patients treated with nilotinib: cross-sectional study.
    Mori H; Sukegawa M; Fukatsu M; Sano T; Takahashi H; Harada K; Kimura S; Ohkawara H; Nakamura K; Mita M; Saito T; Hamazaki Y; Ohta M; Ikezoe T
    Ann Hematol; 2020 Feb; 99(2):359-361. PubMed ID: 31872359
    [No Abstract]   [Full Text] [Related]  

  • 2. Bosutinib in the treatment of chronic myelogenous leukemia.
    Cortes J
    Clin Adv Hematol Oncol; 2012 Nov; 10(11):736-7. PubMed ID: 23271260
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
    Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
    J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
    [No Abstract]   [Full Text] [Related]  

  • 5. Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients.
    Kimura S
    Rinsho Ketsueki; 2009 Jul; 50(7):547-55. PubMed ID: 19638722
    [No Abstract]   [Full Text] [Related]  

  • 6. Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients.
    Hochhaus A; Ernst T; Eigendorff E; La Rosée P
    Ann Hematol; 2015 Apr; 94 Suppl 2():S133-40. PubMed ID: 25814079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
    Thienelt CD; Green K; Bowles DW
    Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New kinase inhibitor approved for CML.
    Traynor K
    Am J Health Syst Pharm; 2012 Nov; 69(21):1846. PubMed ID: 23111662
    [No Abstract]   [Full Text] [Related]  

  • 9. Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
    Yilmaz M; Jabbour E
    Semin Oncol; 2015 Dec; 42(6):876-86. PubMed ID: 26615132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing tolerability of TKI therapy in CML.
    Hochhaus A
    Blood; 2014 Feb; 123(9):1284-5. PubMed ID: 24578491
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chronic Myelogenous Leukemia].
    Hochhaus A; Eigendorff E; Ernst T
    Dtsch Med Wochenschr; 2018 Sep; 143(18):1304-1310. PubMed ID: 30199910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
    Hall KH; Brooks A; Waller EK
    Am J Hematol; 2021 Aug; 96(8):E293-E295. PubMed ID: 33971041
    [No Abstract]   [Full Text] [Related]  

  • 13. Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.
    Redaelli S; Boschelli F; Perini P; Pirola A; Viltadi M; Gambacorti-Passerini C
    Leukemia; 2010 Jun; 24(6):1223-7. PubMed ID: 20445575
    [No Abstract]   [Full Text] [Related]  

  • 14. Chronic myeloid leukemia with a novel e8a1 BCR-ABL1 fusion: rapid molecular response with nilotinib.
    Crampe M; Shakkak F; Kelly J; Hodgson A; Langabeer SE
    Leuk Lymphoma; 2017 Sep; 58(9):1-6. PubMed ID: 28121203
    [No Abstract]   [Full Text] [Related]  

  • 15. Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome.
    Mirault T; Rea D; Azarine A; Messas E
    Eur J Haematol; 2015 Apr; 94(4):363-7. PubMed ID: 24797802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitor-associated syndrome of inappropriate secretion of anti-diuretic hormone.
    Hill J; Shields J; Passero V
    J Oncol Pharm Pract; 2016 Oct; 22(5):729-32. PubMed ID: 26089312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
    Klyuchnikov E; Schafhausen P; Kröger N; Brummendorf TH; Osanmaz O; Asenova S; Zabelina T; Ocheni S; Ayuk F; Zander AR; Bacher U
    Acta Haematol; 2009; 122(1):6-10. PubMed ID: 19602874
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.
    Gora-Tybor J; Medras E; Calbecka M; Kolkowska-Leśniak A; Ponikowska-Szyba E; Robak T; Jamroziak K
    Leuk Lymphoma; 2015; 56(8):2309-14. PubMed ID: 25563556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
    Gover-Proaktor A; Granot G; Pasmanik-Chor M; Pasvolsky O; Shapira S; Raz O; Raanani P; Leader A
    Leuk Lymphoma; 2019 Jan; 60(1):189-199. PubMed ID: 29741440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
    Caocci G; Mulas O; Abruzzese E; Iurlo A; Annunziata M; Orlandi EM; Galimberti S; Binotto G; Sgherza N; Luciano L; Martino B; Russo Rossi A; Bonifacio M; Fozza C; Trawinska MM; Cattaneo D; Elena C; Baratè C; De Gregorio F; Molica M; La Nasa G; Foà R; Breccia M
    Ann Hematol; 2019 Aug; 98(8):1885-1890. PubMed ID: 31044260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.